News and Information

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

Dendreon has reached agreements with certain of its senior noteholders on the terms of a financial restructuring. Operations will continue in the ordinary course and PROVENGE will remain available. Additional information about the financial restructuring is available here:

View all »   RSSRecent Releases

Feb 10, 2015
Dendreon Announces Expiration of Bid Deadline In Connection With Agreement to Sell Substantially All Assets to Valeant

Feb 5, 2015
Dendreon Enters into Amended Agreement with Valeant in Connection with Court-Supervised Sales Process

Jan 29, 2015
Dendreon Reaches Agreement For Valeant To Serve As "Stalking Horse Bidder" In Court-Supervised Sales Process

Presentations and Information

Stipulation of Settlement of Certain Shareholder Litigation PDF 3.9 MB
MEDCAC 11.17.10 Presentation PDF 397.5 KB
Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC) PDF 421.1 KB